

Introducing New Study Concepts: A Community Engagement Perspective




Community Advisory Board members at the Kisumu CRS offices

When a new study concept is introduced, a critical component of the process is engaging study communities. Helping community members understand the benefits and risks of study participation allows them to make decisions about how they want to support or contribute to a study's development. Whether a new drug, treatment method or technology, the messaging process is critical, and consultation at the protocol development stage is essential. The community engagement team at the KEMRI Centre for Global Health, aka Kisumu Clinical Research Site (CRS), in Kisumu, Kenya, regularly engage community stakeholders, including women, youth, female sex workers, and men who have sex with men.

[Read More](#)

COVID-19 Guidance and Resources



Check out the HPTN COVID-19 Resource Center for the latest clinical trials guidance and publications, webinars and media coverage featuring HPTN researchers.

[Read More](#)

Remembering Gita Ramjee

Gita Ramjee, PhD, known for her extensive work in HIV prevention and a valued colleague to so many in the HIV Vaccine and Prevention Trials Networks (HVTN and HPTN), sadly succumbed to complications associated with SARS-CoV-2 infection (COVID-19).



[Read Remembrance Letter to Networks](#)

Shoutout



Congratulations to the [HPTN 091](#) study team for reaching protocol V1.0. The Vanguard feasibility and acceptability study is investigating the integration of HIV prevention, gender-affirmative medical care, and peer health navigation to prevent HIV acquisition and transmission for transgender women.

Network Member Spotlight

Sean P. Sylve, a member of the [HPTN 083](#) Community Working Group, is a clinical research and community engagement specialist in the Section of Adolescent Medicine in the Department of Pediatrics at Tulane University School of Medicine in New Orleans. He has been at the forefront of community organization, mobilization, HIV prevention and research in New Orleans for more than a decade. It is his goal to affect change in New Orleans by using community engagement and culture, specifically the house ball community, to mediate biomedical prevention efforts and reduce the disproportionate burden of HIV on Black and Hispanic/Latino LGBTQI+ people.



[Read More](#)

Awareness Days



Hot Off The Press

Brault MA, Spiegelman D, Abdool Karim SS, Vermund SH. [Integrating and Interpreting Findings from the Latest Treatment as Prevention Trials](#). Curr HIV/AIDS Rep. 2020 Apr 16.

Bekker LG, Li S, Pathak S, Tolley EE, Marzinke MA, Justman JE, Mgodini NM, Chirenje M, Swaminathan S, Adeyeye A, Farrior J, Hendrix CW, Piwowar-Manning E, Richardson P, Eshelman SH, Redinger H, Williams P, Sista ND; HPTN 076 Study Team. [Safety and tolerability of injectable Rilpivirine LA](#)

[in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women](#). EClinicalMedicine. 2020 Apr 6;21:100303.

Floyd S, Shanaube K, Yang B, Schaap A, Griffith S, Phiri M, Macleod D, Sloat R, Sabapathy K, Bond V, Bock P, Ayles H, Fidler S, Hayes R; HPTN 071 (PopART) study team. [HIV testing and treatment coverage achieved after 4 years across 14 urban and peri-urban communities in Zambia and South Africa: An analysis of findings from the HPTN 071 \(PopART\) trial](#). PLoS Med. 2020 Apr 2;17(4):e1003067.



What would you like to see from our newsletters? Please e-mail us with your thoughts and ideas at news@hptn.org.

Copyright © 2020 The HIV Prevention Trials Network, All rights reserved.